ArticleJournal of comparative effectiveness research2024
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 14.
Article in Journal of comparative effectiveness research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- R WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 28.Journal of comparative effectiveness research · 2026Article
- R WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 25.Journal of comparative effectiveness research · 2026Article
- R WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 21.Journal of comparative effectiveness research · 2025Article
- R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 19.Journal of comparative effectiveness research · 2025Article
- Effectiveness of chemotherapy with/without radiotherapy for stage IVb esophageal squamous cell carcinoma: a population-based target trial emulation study.Discover oncology · 2025Article
- Stereotactic ablative radiotherapy versus conventional fractionated radiotherapy for clinical early-stage non-small-cell lung cancer: a population-based study.Thoracic cancer · 2024Article
- R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 15.Journal of comparative effectiveness research · 2024Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this latest update we highlight: a publication from the US FDA regarding the definitions of real-world data (RWD) and real-world evidence (RWE); a publication from academic researchers on a demonstration project for target trial emulation; a publication from the National Institute of Health and Care Excellence (NICE) on the 1 year anniversary of their RWE framework; and a publication from NICE and Flatiron Health on the utility of US RWD for initial UK health technology assessment decision making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.